Point72 Asset Management L.P. Buys Shares of 2,422,728 CureVac (NASDAQ:CVAC)

Point72 Asset Management L.P. acquired a new stake in CureVac (NASDAQ:CVAC - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,422,728 shares of the company's stock, valued at approximately $8,237,000. Point72 Asset Management L.P. owned 1.08% of CureVac at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Signaturefd LLC lifted its stake in CureVac by 232.0% in the second quarter. Signaturefd LLC now owns 22,043 shares of the company's stock valued at $75,000 after acquiring an additional 15,403 shares during the last quarter. Ballentine Partners LLC acquired a new stake in CureVac in the first quarter valued at $38,000. Aristides Capital LLC acquired a new stake in CureVac in the fourth quarter valued at $100,000. Tidal Investments LLC acquired a new stake in CureVac in the first quarter valued at $175,000. Finally, Vanguard Personalized Indexing Management LLC lifted its stake in CureVac by 99.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 44,044 shares of the company's stock valued at $147,000 after acquiring an additional 21,999 shares during the last quarter. Institutional investors own 17.26% of the company's stock.

CureVac Stock Performance

CureVac stock traded up $0.03 during midday trading on Wednesday, hitting $3.00. The company's stock had a trading volume of 364,853 shares, compared to its average volume of 911,956. CureVac has a 1-year low of $2.21 and a 1-year high of $6.44. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.28. The company has a 50-day moving average price of $3.24 and a two-hundred day moving average price of $3.26. The company has a market cap of $671.64 million, a price-to-earnings ratio of -2.26, a PEG ratio of 2.19 and a beta of 2.62.

CureVac (NASDAQ:CVAC - Get Free Report) last issued its quarterly earnings data on Thursday, August 15th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.06). CureVac had a negative return on equity of 57.18% and a negative net margin of 422.66%. The business had revenue of $15.55 million during the quarter, compared to analyst estimates of $10.07 million. As a group, sell-side analysts predict that CureVac will post 0.05 earnings per share for the current year.

Analysts Set New Price Targets

Separately, JMP Securities restated a "market outperform" rating and set a $16.00 target price on shares of CureVac in a research note on Monday, September 16th.

CureVac Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.